Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Update

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) saw a large growth in short interest in the month of November. As of November 30th, there was short interest totalling 22,800 shares, a growth of 31.0% from the November 15th total of 17,400 shares. Based on an average trading volume of 2,580,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 1.4% of the shares of the company are sold short.

Galmed Pharmaceuticals Trading Up 5.5 %

NASDAQ GLMD traded up $0.16 during trading hours on Friday, reaching $2.97. 31,667 shares of the company’s stock were exchanged, compared to its average volume of 714,124. The firm has a fifty day moving average of $3.32 and a 200-day moving average of $3.96. Galmed Pharmaceuticals has a one year low of $2.56 and a one year high of $23.80. The stock has a market cap of $1.90 million, a PE ratio of -0.18 and a beta of 0.75.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on Galmed Pharmaceuticals in a research report on Wednesday, October 9th. They issued a “sell” rating for the company.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.